ARC-AAT Injection

DRUG2 trials

Sponsors

Arrowhead Pharmaceuticals

Conditions

Alpha-1 Antitrypsin Deficiency

Phase 1

A Study of ARC-AAT in Healthy Volunteer Subjects and Patients With Alpha-1 Antitrypsin Deficiency (AATD)

TerminatedNCT02363946

Arrowhead PharmaceuticalsAlpha-1 Antitrypsin Deficiency

Start: 2015-02-28End: 2016-11-30Updated: 2026-01-12

Phase 2

Safety, Tolerability and Effect of ARC-AAT Injection on Circulating and Intrahepatic Alpha-1 Antitrypsin Levels

WithdrawnNCT02900183

Arrowhead PharmaceuticalsAlpha-1 Antitrypsin Deficiency

Start: 2016-10-31End: 2016-11-30Updated: 2025-12-18

Related Papers

Hepatic-targeted RNA interference provides robust and persistent knockdown of alpha-1 antitrypsin levels in ZZ patients.

2018-03-2148 citations